Roche's Tecentriq cocktail hops into the FDA fast lane for another Merck showdown

tecentriq
Roche is now expecting word from the FDA on its Tecentriq-Avastin-chemo combo by early September. (Roche)

Roche’s Tecentriq-Avastin-chemo combo may have just scored quicker trip into the first-line lung cancer arena.

The company said Monday that the triplet won FDA priority review for previously untreated patients with advanced lung cancer, and that means it could go toe-to-toe with Merck & Co. by Sept. 5.

The regulatory boost follows data rolled out in late March, which showed the trio topped an Avastin-chemo combo at prolonging lung cancer patients’ lives. That survival benefit extended across various subgroups, too—including patients with tumors expressing varying levels of PD-L1, the biomarker Tecentriq is designed to target.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

If Roche can snag an FDA green light, it could mean new life for Avastin, an elder member of the Basel, Switzerland-based company’s cancer lineup. The agency has already approved Mvasi, a biosimilar version of the drug from Amgen and Allergan, in all of Avastin’s currently approved indications, including those in colorectal, lung, kidney and cervical cancers.

RELATED: Roche's latest Tecentriq results shed little light on the lung cancer market race: analyst

The Roche regimen will have to go up against formidable competition from Merck, though. The drugmaker already has first-line approvals for solo immuno-oncology star Keytruda and a combo of Keytruda and chemo, and both treatment options have put up big efficacy numbers.

RELATED: 2018 is here. Now get ready for ‘market-defining’ I-O readouts

Of course, until Roche puts out data on a Tecentriq-chemo pairing—sans Avastin—it’ll be an apples-to-oranges comparison with Merck’s chemo combo. Investors will be watching closely for those results, which are expected later this year.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.